CKI-7 free base|120615-25-0|-陌孚医药/Medlife

您当前的位置：

CKI-7 free base

目录号: PL11005 纯度: ≥99%

CAS No. :120615-25-0

商品编号	规格	价格	会员价
PL11005-5mg	5mg	¥1050.91	请登录
PL11005-10mg	10mg	¥1854.55	请登录
PL11005-25mg	25mg	¥4636.36	请登录
PL11005-50mg	50mg	¥7727.27	请登录
PL11005-100mg	100mg	¥13847.27	请登录
PL11005-200mg	200mg	询价	询价
PL11005-500mg	500mg	询价	询价
PL11005-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1943.56	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	CKI-7 free base
中文别名	蛋白激酶抑制剂CKI-7(PKI)
英文名称	CKI-7 free base
英文别名	N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide;N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide;CKI-7;8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro-;2csn;8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro;CKI;N-(2-Aminoethyl)-5-chloro-8-isoquinolinesulfonamide;N-(2-AMinoethyl)-5-chloro-isoquinolin-8-sulphonaMide;8-[N-(2-Aminoethyl)sulphamoyl]-5-chloroisoquinoline, CKI-7;8-Isoquinolinesulfonamide, N-(2-aminoethyl)-5-chloro- Dihydrochloride;CKI-7 free base
Cas No.	120615-25-0
分子式	C₁₁H₁₂N₃O₂Scl
分子量	285.75
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	CKI-7 free base 是一种有效且 ATP 竞争性的酪蛋白激酶 1 (CK1) 抑制剂，IC₅₀ 为 6 μM，K_i 为 8.5 μM。CKI-7 free base 选择性抑制 Cdc7 激酶，还抑制 SGK，S6K1 以及 MSK1。CKI-7 free base 对酪蛋白激酶 II 和其他蛋白激酶的作用弱得多。
生物活性	CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC 50 of 6 μM and a K i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.
性状	Solid
IC50 & Target[1][2]	CK1 6 μM (IC50) CK1 8.5 μM (Ki)
体外研究(In Vitro)	CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner. CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling. has not independently confirmed the accuracy of these methods. They are for reference only. <
体内研究(In Vivo)	In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122(Pt 17):3169-79. [2]. Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11): 2668.

溶解度数据	In Vitro: DMSO : 25 mg/mL (87.49 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation